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Higher eukaryote tRNA synthetases have ex-
panded functions that come from enlarged,
more differentiated structures that were adap-
ted to fit aminoacylation function. How those
adaptations affect catalytic mechanisms is not
known. Presented here is the structure of a cat-
alytically active natural splice variant of human
tryptophanyl-tRNA synthetase (TrpRS) that is
a potent angiostatic factor. This and related
structures suggest that a eukaryote-specific
N-terminal extension of the core enzyme
changed substrate recognition by forming an
active site cap. At the junction of the extension
and core catalytic unit, an arginine is recruited
to replace a missing landmark lysine almost
200 residues away. Mutagenesis, rapid kinetic,
and substrate binding studies support the func-
tional significance of the cap and arginine re-
cruitment. Thus, the enzyme function of human
TrpRS has switched more to the N terminus of
the sequence. This switch has the effect of cre-
ating selective pressure to retain the N-terminal
extension for functional expansion.
INTRODUCTION
Over the eons, aminoacyl-tRNA synthetases developed
expanded functions that are correlatedwithmore differen-
tiated and enlarged structures (Park et al., 2005b). The
synthetases are thought to have been among the first pro-
teins to appear in the transition from the RNA world to the
theater of proteins, where they took over the role of ribo-
zymes in making the genetic code’s connection between
nucleotide triplets and specific amino acids. As the tree
grew out of the last common ancestor and split into the
three great kingdoms, protein networks became the
core of biological systems that enabled the complexity
of the single cell and the development of multicellularStructure 15organisms. The synthetases were adapted to and facili-
tated these networks by providing connections between
translation and the signaling pathways of eukaryotes. In
addition to the novel functions of proteins such as p43
(or AIMP1) (Han et al., 2006), p38 (or AIMP2) (Kim et al.,
2003), and p18 (or AIMP3) (Park et al., 2005a) that are
bound to tRNA synthetases in mammalian cells, human
synthetases with well-documented expanded functions
include Tyr- (Wakasugi and Schimmel, 1999), Trp- (Waka-
sugi et al., 2002), His- (Howard et al., 2002), Lys- (Park
et al., 2005c), and Glu-Pro (Sampath et al., 2004) tRNA
synthetases. In lower eukaryotes, TyrRS, LeuRS, and
GlyRS are well-studied examples (Hsu et al., 2006; Myers
et al., 2002; Johanson et al., 2003).
Here we focus on the question of how the core, indis-
pensable catalytic unit of a tRNA synthetase was adapted
to accommodate these functional expansions. We imag-
ined that selective pressure to retain a functional expan-
sion would be strongest when the essential aminoacyla-
tion function would be lost without retention of the new
function. Thus, structural adaptations, or changes, in the
catalytic unit had to be made in a way that was integrated
with the new function. With this perspective, we chose
the class I tryptophanyl-tRNA synthetase (TrpRS) as an
example.
TrpRS expression, like that of many angiostatic factors,
is induced by interferon-g (Aboagye-Mathiesen et al.,
1999). Whereas the native enzyme is inactive in angio-
genic signaling, an alternative splice fragment (mini-
TrpRS) (Wakasugi et al., 2002) and a natural proteolytic
fragment (T2-TrpRS) are potent angiostatic factors (Otani
et al., 2002) that act through a VE-cadherin receptor and
the Akt signaling pathway (Tzima et al., 2003). Prior struc-
tural work on the human enzyme by us and others (Kise
et al., 2004; Yang et al., 2003; Yu et al., 2004), and exten-
sive work on the bacterial (Bacillus stearothermophilus)
enzyme (Doublie et al., 1995; Ilyin et al., 2000; Retailleau
et al., 2001, 2003, 2007), provided the framework within
which we identified three specific questions.
First, unlike the bacterial enzymes, TrpRS in eukaryotes
and archae have N-terminal extensions. For example, in
basal eukaryotes, such as Giardia lamblia or Saccharo-
myces cerevisiae, TrpRSs have a eukaryote-specific, 793–805, July 2007 ª2007 Elsevier Ltd All rights reserved 793
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TrpRS Active Site Adapted for Cytokine FunctionN-terminal extension of around 100 amino acids, while
vertebrates, such as humans and bovines, have an exten-
sion of about 150 amino acids, composed of the eukary-
ote-specific extension (ESE) and an additional verte-
brate-specific extension (VSE) (Figure 1). In humans, the
VSE is dispensable for the aminoacylation activity, and
yet is critical for regulation of angiogenic signaling (Otani
et al., 2002). Human TrpRS manifests anti-angiogenic ac-
tivity only when the VSE is removed. The natural splice
variant mini-TrpRS (Figure 1) lacks most of the VSE but
contains the ESE and is anti-angiogenic. We imagined
that, to retain the anti-angiogenic activity of mini-TrpRS
that most likely developed through adding the ESE, the
catalytic activity had to be tied to the extension in some
way. Indeed, T2-TrpRS (Figure 1), which comes from
proteolytic removal of 93 (including part of the ESE) of
the additional 150 N-terminal amino acids of human
TrpRS, is inactive for aminoacylation (Otani et al., 2002),
even though T2-TrpRS contains more than the entire
Figure 1. Sequences of TrpRSs from B. stearothermophilus
(Bacterium), S. cerevisiae (Basal Eukaryote), and Human
(Vertebrate)
Human TrpRS has the conservedRossmann fold catalytic domain (yel-
low) and anticodon recognition domain (green) shared by all TrpRSs,
a eukaryote-specific extension (ESE, purple) shared by all eukaryotic
TrpRSs, and a vertebrate-specific extension (VSE, blue) at the N termi-
nus. The natural splice variant mini-TrpRS lacks most of the VSE. The
proteolytic fragment T2-TrpRS lacks the first 93 residues that include
the VSE and part of the ESE. Both fragments of human TrpRS are
angiostatic.794 Structure 15, 793–805, July 2007 ª2007 Elsevier Ltd All rigorthologous sequence of prokaryotic TrpRSs. Thus, we
wondered what makes T2-TrpRS inactive.
Second, human TrpRS is missing one of the hallmarks
of class I tRNA synthetases. The ten class I tRNA synthe-
tases have an 11 amino acid signature sequence that ends
in the tetrapeptide HIGH (Webster et al., 1984) and, later in
the sequence, a KMSKS pentapeptide (Arnez and Moras,
1997). These hallmarks of class I enzymes articulate with
bound ATP and with the adenylate intermediate amino-
acyl-AMP. In particular, in a widely conserved interaction,
the second K of KMSKS binds to ATP phosphates (Retail-
leau et al., 2003). Remarkably, the hallmark pentapeptide
is replaced by a KMSAS peptide in human TrpRS, thus
raising the question of how the critical interaction of the
second K is replaced and whether that replacement might
be relevant to retention of the N-terminal extension.
Third, we were struck by the dramatic conformational
change seen upon substrate (ATP) binding to B. stearo-
thermophilus TrpRS. The structural data show clearly an
induced fit of ATP to the active site, as the enzyme shifts
from an ‘‘open’’ to a ‘‘closed’’ conformation (Retailleau
et al., 2003). Given the absence of the critical second K
in human TrpRS, indicating a change in the way that
ATP is recognized, we wondered whether this induced-
fit mechanism is preserved in human TrpRS.
To pursue these questions, an existing structure of ours
was analyzed beyond what was previously reported,
a structure of a cocrystal of an angiostatic form of TrpRS
was determined, and targeted mutagenesis and func-
tional studies were carried out. These efforts yielded
a much clearer picture of how structural adaptations for
the expanded function of TrpRS became linked to and
necessary for the essential aminoacylation activity.
RESULTS
Framework for Investigating Structural Adaptations
Associated with Expanded Function
Table 1 lists five previously reported structures of human
TrpRSs, including the angiostatic, catalytically active nat-
ural fragment mini-TrpRS (Kise et al., 2004) and the angio-
static, catalytically inactive T2-TrpRS (Yu et al., 2004)
determined by other laboratories, along with a Trp-AMPTable 1. Summary of the Solved Crystal Structures of Human TrpRS
Ligand Resolution (A˚) Varianta PDB Code Reference
Full-length (1–471) Trp-AMP (half-site) 2.1 GD 1R6T Yang et al., 2003
tRNATrp and Trp 2.9 GD 2AZX Yang et al., 2006
Mini-TrpRS (48–471) Not reportedb 2.3 GY 1ULH Kise et al., 2004
Trp-AMP (half-site) 1.9 GD 1R6U This work
T2-TrpRS (94–471) None 2.5 SY 1O5T Yu et al., 2004
tRNATrp and Trp 3.0 SY 2AKE and 2DR2 Shen et al., 2006
a Sequence variations at residues 213 and 214 are due to apparent polymorphism (Ewalt et al., 2005).
bMini-TrpRS(GY) was reported as an apo proteinwithout bound ligand. However, the crystal lattice, the space group, and the struc-
ture are almost identical to what is reported here on the mini-TrpRS(GD)/Trp-AMP complex. Through personal communications,
O. Nureki confirmed that a half-site Trp-AMP was also found in their structure, which had been previously overlooked.hts reserved
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TrpRS Active Site Adapted for Cytokine FunctionFigure 2. Overall Structure of TrpRSs
(A) Crystal structure of the dimeric full-length human TrpRS that is bound with Trp-AMP in one of the two subunits. The VSE forms the N-terminal
appended domain, and the ESE folds into the eukaryote-specific patch.
(B) Electron density of bound Trp-AMP.
(C) Crystal structure of the dimeric human mini-TrpRS that lacks the N-terminal appended domain. Mini-TrpRS also contains Trp-AMP bound to one
subunit.
(D) For comparison, the crystal structure of the B. stearothermophilus TrpRS/Trp-AMP complex solved by Retailleau et al. (2001) is shown.cocrystal structure of the full-length enzyme reported by
this laboratory (Yang et al., 2003). A structure of mini-
TrpRS bound with Trp-AMP, which would help to clarify
the role of the VSE in the context of bound Trp-AMP, is
added to the list by the work reported here. We assimi-
lated this structure with the previous ones to establish
a perspective from which we were able to design specific
experiments to further explore and understand the re-
markable structural adaptations of the active site that
accompanied functional expansion.
Like the bacterial ortholog (Doublie et al., 1995), human
TrpRS is a homodimer, with the dimer interface formed by
an insertion known as connective polypeptide 1 (CP1) into
the Rossmann fold that harbors the active site region. The
dimeric full-length TrpRS was accommodated in the crys-
tallographic asymmetric unit (Figure 2A). Subunit A was
resolved in its entirety and includes the VSE forming the
N-terminal appended domain (Ala7-Ala60), the ESE fold-
ing into the eukaryote-specific patch (Glu82-Lys154)
associated closely with the Rossmann fold catalytic do-
main (Pro155-Ser353) that is orthologous to the bacterial
(B. stearothermophilus) enzyme, and the anticodon recog-
nition domain (Asp354-Ala467).Structure 1Between the N-terminal appended domain and the
eukaryote-specific patch of human TrpRS, a disordered
region of 21 residues (Asp61-Glu81) appears to form a
flexible linker. Subunit A bound a complete density for
Trp-AMP (Figures 2A and 2B). The atomic temperature
factors for the single Trp-AMP ligand were some of the
lowest in the molecule and were similar to those of
the adjacent protein side chains. Thus, this binding site
appears to be fully occupied. In subunit B, the first 96 res-
idues—which include the N-terminal appended domain,
the flexible linker, and part of the eukaryote-specific
patch—were completely disordered. In addition, subunit
B did not contain Trp-AMP and, consistently, part of
the KMSKS loop (Ala346-Asp354) of subunit B was
disordered.
VSE Forms an N-Terminal Appended Domain
The VSE in human TrpRS is a member of the WHEP-TRS
conserved domain family (pfam00458) (Bateman et al.,
2002). Homologs of this domain are found in several other
human aminoacyl-tRNA synthetases, including those for
glycine, histidine, and methionine (Ge et al., 1994; Hira-
kata et al., 1996; Tsui and Siminovitch, 1987) and as5, 793–805, July 2007 ª2007 Elsevier Ltd All rights reserved 795
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TrpRS Active Site Adapted for Cytokine Functiona linker domain fusing together the two synthetases of the
naturally occurring, bifunctional glutamyl-prolyl-tRNA
synthetase (Glu-ProRS) (Fett and Knippers, 1991; Rho
et al., 1998). The VSE formed a helix-turn-helix structure
(Figure 2A) that was similar to the structure (determined
by NMR) for an isolated peptide of the first WHEP-TRS re-
peat from the linker region of human Glu-ProRS (Jeong
et al., 2000). The two structures superposed with a root-
mean-square (rms) deviation of 1.49 A˚ for 53 Ca atoms.
Two long a helices (a1 and a2) of the helix-turn-helix struc-
ture were of equal length (21 residues) and almost parallel
to each other. The C-terminal part of a1 and the loop
region connecting a1 and a2 were located close to the
Rossmann fold and the first few residues of the anticodon
recognition domain, with several contacts within H-bond-
ing distance. This dispensable (for aminoacylation)
domain was linked to the rest of the enzyme via the
aforementioned flexible linker, and it was completely dis-
ordered in the B subunit, suggesting that the location of
this N-terminal appended domain could be flexible relative
to the rest of the enzyme.
Retained Binding of Trp-AMP Revealed
in the Mini-TrpRS Structure
Themajority of VSE is removed in the natural splice variant
mini-TrpRS, and we wanted to evaluate whether this dele-
tion of the VSE affected the conformation or ligand bind-
ing. Our previous cocrystal of the full-length TrpRS bound
to Trp-AMPwas obtained serendipitously, due to trapping
of the reaction intermediate in the absence of its cognate
tRNA (Ewalt et al., 2005). Mini-TrpRS was overexpressed
and purified using the same procedure as for the full-
length enzyme. Both forms of TrpRS were able to amino-
acylate the cognate tRNATrp in the absence of added Trp
and ATP, indicating that mini-TrpRS also bound and
sequestered Trp-AMP.
We obtained cocrystals of mini-TrpRS, and its structure
was solved by molecular replacement at 2 A˚ using a start-
ing model derived from full-length TrpRS (Table 2). Except
for the absence of the N-terminal appended domain, the
structure of mini-TrpRS was almost identical to full-length
TrpRS (Figure 2C). Superposition of the two structures
showed an rms deviation of only 0.58 A˚ for all 748 equiva-
lent Cas. Mini-TrpRS also had a ‘‘half-site’’ Trp-AMP-
bound dimer accommodated in the asymmetric unit. The
unbound subunit was more disordered than its bound
counterpart, in a way similar to what was observed for
the full-length enzyme.
As compared with the density in full-length TrpRS, the
half-site-bound Trp-AMP in mini-TrpRS has an incom-
plete electron density for the AMP moiety. Residues sur-
rounding the AMPmoiety have higher temperature factors
than residues neighboring the well-resolved tryptophan
moiety and, in general, mini-TrpRS had higher tempera-
ture factors (Table 1) than the full-length TrpRS (cf Kise
et al., 2004). Therefore, the incomplete density of Trp-
AMP in the cocrystal with mini-TrpRS was likely due to
partial disorder of the active site. This observation sug-
gested that the VSE of full-length TrpRS helped to stabilize796 Structure 15, 793–805, July 2007 ª2007 Elsevier Ltd All rigthe binding site. However, as reported earlier (Yang et al.,
2006), deletion of the VSE did not change the apparent Km
for tRNA or the kcat for aminoacylation. Thus, while the
VSE appears to provide some stability to the overall struc-
ture, including the active site, the primary function of VSE
appears to be to regulate cytokine activity.
Eukaryote-Specific Patch and Its Functional Role
The eukaryote-specific patch extends from Glu82 to
Lys154. In the three-dimensional structure, the patch is
intimately associated with the Rossmann fold to form an
integrated catalytic domain (Figures 2A and 2C). A b1-b2
Table 2. Data Collection and Refinement Statistics of
Mini-TrpRS Complexed with Trp-AMP
Data Collection
Space group C2
a (A˚) 134.7
b (A˚) 96.5
c (A˚) 97.1
b () 129.9
Wavelength (A˚) 0.9116
Resolution (A˚) 2.0
Unique reflections 64,590
Completeness (%)a 99.5 (99.6)
Redundancy 7.3
Rmerge (%)
a,b 3.8 (58.7)
< I/s(I) >a 34.7 (2.0)
Refinement Statistics
Resolution range (A˚) 20–2.0
Rwork/Rfree (%)
c 25.35/29.75
Rms deviation bond lengths (A˚) 0.007
Rms deviation bond angle () 1.3
Ramachandran plot (%)
Favored 90.1
Allowed 8.8
Generously allowed 1.0
Disallowed 0.2
Average B factors for protein (A˚2) 50.9
Average B factors for substrate (A˚2) 53.5
Average B factors for waters (A˚2) 42.5
aNumbers in parentheses refer to the highest resolution shell.
b Rmerge = (ShSijIi(h) < I(h) >j/ShSiIi(h))3 100, where < I(h) > is
the average intensity of I symmetry-related observations of re-
flections with Bragg index h.
cRwork = (ShkljFo Fcj/ShkljFoj)3 100, where Fo and Fc are the
observed and calculated structure factors, respectively, for
95% of the reflections used in the refinement. Rfree was calcu-
lated as for Rwork but on 5% of reflections excluded before
refinement.hts reserved
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TrpRS Active Site Adapted for Cytokine FunctionFigure 3. Trp-AMP Binding Site
(A and B) The Trp-AMP binding site of human
TrpRS (A) and B. stearothermophilus TrpRS
(B).
(C) H-bonding interactions with Trp-AMP at the
active site of human TrpRS.hairpin from the eukaryote-specific patch covers the ac-
tive site that otherwise would be exposed (Figure 3A).
(Figure 3B is the comparable region from the B. stearo-
thermophilus enzyme.) Two residues, Pro87 and Trp88,
which are located at the loop of the b1-b2 hairpin, make
water-mediated H-bonding interactions with the a-amino
group and carbonyl oxygen of the Trp moiety of bound
Trp-AMP (Figure 3C).
T2-TrpRS, which starts at Ser94 and lacks the b hairpin
(Figure 1), is a perfect construct for investigating the role of
the b hairpin of the eukaryote-specific patch. As, when the
b hairpin is removed, the ATP binding site seems to be
more exposed than the Trp binding site (Figure 3A), we hy-
pothesized that the absence of the b1-b2 hairpin might
weaken ATP binding that, in turn, would affect the ability
to synthesize Trp-AMP. At the same time, the portion of
the active site that interacts with tryptophan appears
less disturbed in T2-TrpRS (Figure 3A).
To test this hypothesis, we used isothermal titration cal-
orimetry (ITC) to measure the affinity of T2-TrpRS for ATP
and Trp. The same experiments were carried out, for com-
parison, with full-length TrpRS. In these experiments, we
observed binding of ATP to the full-length enzyme (at pH
7.5, 25C) with an apparent Kd = 20 mM. In contrast, T2-
TrpRS had a more than 25-fold reduced affinity for ATP
(apparent Kd > 0.5 mM). On the other hand, T2-TrpRS
and full-length TrpRS had comparable affinities for TrpStructure 15(apparent Kd = 11.3 mM for T2-TrpRS versus apparent
Kd = 6.8 mM for TrpRS). These experiments are consistent
with the b1-b2 hairpin of the eukaryote-specific patch
playing an important role in the binding of ATP.
A Distal Arginine Is Proposed as a Surrogate
for the Missing Landmark Lysine
As mentioned above, the critical second K of the KMSKS
motif of class I tRNA synthetases is missing in human
TrpRS, which has a K349MSAS pentapeptide. To better
understand how compensation for the missing K was
achieved, we examined amino acid residues that poten-
tially interact with the phosphates of ATP in human TrpRS
compared to B. stearothermophilus TrpRS. A human
TrpRS/ATP complex model was built (Figure 4A) based
on the B. stearothermophilus TrpRS/ATP cocrystal struc-
ture (Retailleau et al., 2003) (Figure 4B). The modeling was
done by overlapping the adenosine moiety of ATP from
the closed B. stearothermophilus TrpRS/ATP complex
(PDB code: 1M83) with the same moiety of the bound
Trp-AMP in the human TrpRS structure. The result of
this procedure was that the phosphates of ATP were fully
engaged by the human TrpRS, with optimal phosphate-
protein interactions. Therefore, the model is a plausible
representation of the actual complex, and supports the
idea that the solved TrpRS conformation with bound, 793–805, July 2007 ª2007 Elsevier Ltd All rights reserved 797
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TrpRS Active Site Adapted for Cytokine FunctionTrp-AMP is similar to an ATP-bound conformation, at least
in the active site.
The model also confirmed a role for the b1-b2 hairpin in
ATP binding. The backbone carbonyl oxygen of Pro87 in
the loop of the hairpin interacts with the phosphates of
ATP via Mg2+ coordination (Figure 4A). In fact, we ob-
served by ITC that T2-TrpRS had only slightly decreased
affinity for Trp-sulfamino-adenosine (a nonhydrolyzable
Trp-AMP analog), when compared with the full-length en-
zyme (data not shown). Thus, the experiment showed that
binding to the AMP moiety of ATP was not affected by
Figure 4. ATP Binding Site
Comparison between human TrpRS (A) and B. stearothermophilus
TrpRS (B) of the binding site for ATP phosphates. Among other substi-
tutions, Arg162 in human TrpRS takes the role of Lys195 of KMSK195S
in B. stearothermophilus TrpRS.798 Structure 15, 793–805, July 2007 ª2007 Elsevier Ltd Allremoval of the b hairpin. This result is consistent with crys-
tal structures of mini- and full-length TrpRS at the Trp-
AMP binding site, where it is clear that all the interactions
with the AMP moiety are from residues of the Rossmann
fold (Figure 3C), which is intact in T2-TrpRS. Therefore,
the b hairpin plays a key role in ATP binding by interacting
only with its phosphate groups.
Interestingly, based on the model, Arg162 of human
TrpRS seemed to take the role of Lys195 in B. stearother-
mophilus TrpRS (the second K of K192MSKS). Arg162 is
located a few residues beyond the end of the eukaryote-
specific patch, immediately after the first b strand (b5) of
the Rossmann fold that is shared by all TrpRSs through
evolution. In three-dimensional space, Arg162 is located
directly across from the KMSAS signature in human
TrpRS, and is modeled to form salt bridges with both
a- and b-phosphates of ATP (Figure 4A), as does Lys195
of B. stearothermophilus TrpRS (Figure 4B). However,
Arg162 in human TrpRS approaches the phosphates of
ATP from the opposite side as the approach of Lys195
in bacterial TrpRS. For another phosphate interaction,
Lys200 of human TrpRS replaced Gln9 in B. stearother-
mophilus TrpRS.
Mutational and Functional Analysis
of the Role of Surrogate Arginine
Supporting their importance, all the phosphate-interacting
residues suggested by the model, including Arg162 and
Lys200, are strictly conserved in all available sequences
of eukaryotic TrpRSs. To test the hypothesis that Arg162
is a surrogate for the second Lys of the KMSKS pentapep-
tide, R162A TrpRS was created. Stopped-flow kinetics
was used to study the pre-steady-state kinetics of Trp ac-
tivation (Trp + ATP/ Trp-AMP), using the R162A mutant
protein in comparison with the wild-type enzyme. In these
experiments, the R162A mutation decreased the ATP
binding affinity about 60-fold, from an apparent KM =
2 mM (wild-type) to 115 mM (R162A mutant) (Table 3).
(The KM of the wild-type enzyme is comparable to theTable 3. Pre-Steady-State Kinetic Analysis of the Tryptophan Activation Reaction by Stopped-Flow Kinetics
TrpRS KATP (mM) kf1 (s
1)c
Wild-type 2.0 (±0.3)a,b 13 (±0.8)
R162A 115 (±29) 0.05 (±0.007)
R162A/A352K 2.8 (±1.2) 0.01 (±0.001)
At room temperature (23C) and pH 8.0.
a Standard errors for curve fitting of three repeated experiments are indicated in parentheses.
b The KM for ATP is much higher than the Kd measured by ITC. This relationship between KM and Kd is seen for many enzymes and,
in this particular instance, is likely because, in the kinetic studies, the conversion of boundATP to the Trp-AMPproduct occursmore
rapidly than the dissociation of free ATP from the enzyme. This conversion, in effect, sharply raises the apparent dissociation rate
constant, giving rise to a KM that is much higher than the Kd (Cantor and Schimmel, 1980). In addition, for reasons of technical con-
venience, conditions for the two experiments were somewhat different (e.g., pH 7.5 for ITC versus pH 8.0 for this kinetic study).
c The kf1 values are calculated based on a KM of 2.5 mM for tryptophan (Ewalt et al., 2005).rights reserved
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2005). The apparent forward rate of activation was re-
duced more than 260-fold, from 13 s1 (wild-type) to
0.05 s1 (R162A mutant).
As a further test of our hypothesis, we asked whether an
A352K substitution could rescue the ATP binding of the
R162A mutant enzyme. The A352K mutation restores
the second lysine to convert the K349MSAS loop back to
KMSKS. This substitution, to yield an R162A/A352K en-
zyme, gave an apparent KM(ATP) = 2.8 mM, and thus al-
most fully rescued the decreased ATP binding of the
R162A synthetase (Table 3). (However, the efficient catal-
ysis represented by the forward rate was not rescued,
thus showing that, even with a second lysine, efficient
catalysis was difficult to achieve in the context of other
adaptive changes occurring in human TrpRS.) These
experiments support strongly the idea that, for ATP inter-
actions, Arg162 is a surrogate for the missing landmark K.
Global Structural Comparison with Bacterial TrpRS
Next, we investigated whether the adaptive changes in
human TrpRS that altered the way that a key ligand—
ATP—was recognized could, in turn, have consequences
for the mechanism of ligand binding. As shown above,
these adaptive changes include the novel role of the
eukaryote-specific patch and the recruitment of a distal
arginine to replace a critical, landmark lysine. For this pur-
pose, we compared the structure of human TrpRS to that
of B. stearothermophilus TrpRS in the core domain. As
mentioned earlier, the bacterial enzyme is one of the clear-
est examples of ligands binding through an induced-
fit mechanism. The question we raised was whether that
mechanism could be preserved, given the constraints in-
troduced by the adaptations of the human enzyme.
Figure 5 shows structure-based alignment of the two or-
thologs, with secondary structure elements of the human
enzyme aligned on top. The sequence of S. cerevisiae
TrpRS is added to the alignment for comparison with a
basal eukaryote. Despite the similarity of the human and
bacterial structures, three major variations were found be-
tween them (besides the N-terminal extension that is not
present in the bacterial enzyme). These variations are des-
ignated V1, V2, and V3 (Figure 5). The residues of V1 be-
tween a12 and a13 in human TrpRS (Gly265-Cys274)
had a loop-turn structure (Figures 2A, 2C, and 3A). By
comparison, the corresponding region inB. stearothermo-
philus TrpRS (Arg104-Ser119) is six residues longer, with
a loop-helix structure covering the active site (Figures
2D and 3B). This region in B. stearothermophilus TrpRS
is lysine rich and, in particular, Lys111 was shown to
form a salt bridge with the g-phosphate of ATP in the
closed TrpRS/ATP complex (Figure 4B) and to play a crit-
ical role in the ATP binding-induced conformational
change (Kapustina and Carter, 2006). In human TrpRS,
the V1 region—including Lys111—is functionally replaced
by the b1-b2 hairpin from the eukaryote-specific patch, as
shown above (Figures 3A, 3B, and 4).
Residues of V2 in human TrpRS (Asn291-Gln304) had
an 11 residue insertion compared with the equivalentStructure 15region (Tyr136-Thr138) in B. stearothermophilus TrpRS
(cf Kise et al., 2004). The helix-loop structure of this inser-
tion blocks the C terminus of the anticodon recognition
domain from extending to the dimerization interface.
As a result, the shorter C terminus of human TrpRSmoves
away and ends next to the central b sheet of the Ross-
mann fold domain (Figures 2A and 2C). In contrast, the
longer C-terminal helix of B. stearothermophilus TrpRS
extends toward the other subunit and expands the CP1 di-
merization interface (Figure 2D). Therefore, the buried area
in the human TrpRS dimerization interface is considerably
smaller (1328 A˚2) compared to the area in B. stearother-
mophilus TrpRS (1812 A˚2).
Residues of V3 include Arg381-Val396 from the anti-
codon recognition domain of human TrpRS and have a
different structure and spatial location compared to
the equivalent region in B. stearothermophilus TrpRS
(Glu225-Ile238) (Figures 2A, 2C, and 2D). Using basically
the same conformation observed here, this region of
human TrpRS (a17) was seen involved with anticodon rec-
ognition in the structure with bound tRNA (Yang et al.,
2006). (The equivalent region in TyrRS from Methanococ-
cus jannaschii was also seen involved in recognizing the
anticodon of its cognate tRNA; Kobayashi et al., 2003.)
As discussed previously (Yang et al., 2006), this region
of B. stearothermophilus TrpRS may undergo a tRNA-
induced conformational change, and the induced con-
formation is likely to resemble that found in the cocrystal
of human TrpRS with tRNATrp.
Active Site Comparison with Bacterial TrpRS
Consistent with the low sequence similarity between eu-
karyotic and prokaryotic TrpRSs (11% identity between
the sequences of human and B. stearothermophilus
TrpRS), the active site residues involved in tryptophan
binding were not significantly conserved across the two
kingdoms (Figures 6A and 6B). Among the eight residues
in human TrpRS (i.e., Pro87, Trp88, Tyr159, Gln194,
Glu199, Gln284, Gln313, and Tyr316) that interacted
with the Trp moiety via H bonding or water-mediated H
bonding, only Gln313 had its equivalent in B. stearother-
mophilus TrpRS (Gln147). On the other hand, interactions
mediating AMP binding were conserved (Figures 6C and
6D). All eight residues in human TrpRS (i.e., Thr160,
Gly161, His170, Ala310, Asp312, Phe340, Lys349, and
Met350) that interacted with the adenine base and ribose
moiety (via H bonding or water-mediated H bonding) had
equivalent interactions in B. stearothermophilus TrpRS.
While the amino acids were not strictly conserved, the
type of interaction was shared. For example, Phe340 of
human TrpRS occupied an equivalent position to Ile183
of B. stearothermophilus TrpRS. Both residues donated
an H bond to N1 and accepted an H bond from the N6
amino group of adenine, using their backbone amide ni-
trogen and carbonyl oxygen. Another example is His170
in human TrpRS and the equivalent residue Thr15 in B.
stearothermophilus TrpRS. The side chains of both were
involved in a water-mediated H bond to N7 of adenine., 793–805, July 2007 ª2007 Elsevier Ltd All rights reserved 799
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TrpRS Active Site Adapted for Cytokine FunctionFigure 5. Structural Alignment of Human and B. stearothermophilus TrpRSs
The sequence of S. cerevisiae TrpRS is included in the alignment. Three major variations, V1, V2, and V3 (besides the N-terminal extension), between
eukaryotic and B. stearothermophilus TrpRS are highlighted. Lys195 of B. stearothermophilus TrpRS and its functional substitute Arg162 of human
TrpRS are marked with triangles (green and red, respectively) under the sequences.We hypothesized previously that tyrosine and trypto-
phan differentiation for tRNA synthetases developed late
in evolution (Yang et al., 2003), with plasticity, or adapt-
ability, being a characteristic of this particular amino acid
binding pocket. Consistent with this hypothesis, between
eukaryotes andprokaryotes, residues needed for thebind-
ing of Trpwere less conserved than those for bindingAMP.
Thus, Trp recognition has continuously evolved after the
separation of eukaryotes from prokaryotes.
Human TrpRS Stays in a Closed Conformation and
Uses a Unique Mechanism to Engage the Active Site
B. stearothermophilus TrpRS is one of the most exten-
sively studied aminoacyl-tRNA synthetases, with a series
of crystal structures (Doublie et al., 1995; Ilyin et al., 2000;
Retailleau et al., 2001, 2007), small-angle X-ray scattering800 Structure 15, 793–805, July 2007 ª2007 Elsevier Ltd All rigexperiments, and kinetic and computational studies es-
tablishing that the dimeric enzyme uses an induced-fit
mechanism to activate tryptophan to generate Trp-AMP
(Retailleau et al., 2003; Kapustina and Carter, 2006). An
open form was found in the unliganded or single-liganded
(E, ETrp, or EATP) enzyme (Ilyin et al., 2000). A closed,
pre-transition-state complex was observed with trypto-
phanamide and ATP (ETrp*ATP) and was characterized
by a constrained KMSKS peptide enclosing the active site
cavity (Retailleau et al., 2003). (A similar closed conforma-
tion was observed with the single-ligand complex formed
at high ATP concentration, thus suggesting that, under
some conditions, ATP could also be an allosteric effector.)
Last, a closed conformation was also observed with the
intermediate product Trp-AMP (ETrp-AMP) (Retailleau
et al., 2001). To change between the open and closedhts reserved
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TrpRS Active Site Adapted for Cytokine FunctionFigure 6. Close-Up Views of the Trp-AMP Binding Site of Human and B. stearothermophilus TrpRSs
Human (A and C) and B. stearothermophilus (B and D) TrpRSs. Equivalent residues between the two TrpRSs are boxed, and the purple color-filled
boxes indicate conserved protein-ligand interactions. Clearly, interactions with the Trp moiety are less conserved between human TrpRS (A) and
B. stearothermophilus TrpRS (B), compared to interactions with the AMP moiety (C and D). (To reduce overlap and increase clarity for [C] and [D],
some interactions with the a-phosphate group are illustrated in [A] and [B].)conformations, a hinge-like motion between the Ross-
mann fold domain and the anticodon recognition domain
was needed to open and close the ATP binding cleft
(Figure 7A). These distinct states were proposed to reflect
an induced-fit mechanism whereby ATP binding induced
conformational activation for catalysis.Structure 1We compared the conformational isomers of human
TrpRS with those of B. stearothermophilus TrpRS. (The
structures of human mini-TrpRS were nearly identical to
that of full-length TrpRS, and therefore are omitted
here for discussion.) Superposition of the structures of
Trp-AMP-bound TrpRS subunit A, with ligand-free and5, 793–805, July 2007 ª2007 Elsevier Ltd All rights reserved 801
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TrpRS Active Site Adapted for Cytokine FunctionTrp-AMP-bound B. stearothermophilus TrpRS (open and
closed conformations, respectively), indicated clearly
that human TrpRS was more similar to the Trp-AMP-
bound closed conformation of B. stearothermophilus
TrpRS (Figure 7A). Interestingly, this similarity with the
closed conformation was also seen with ligand-free hu-
man TrpRS subunit B (Figure 7B). Consistently, the struc-
ture of T2-TrpRS (Yu et al., 2004), which was completely
free of ligand, was also in the closed conformation, similar
to that observed with human TrpRS bound with Trp-AMP
(Yang et al., 2003) (Figure 7B). Thus, regardless of sub-
strate binding, human TrpRS can exist in a conformation
similar to the closed conformation of bacterial TrpRS.
As shown above, however, ATP or Trp-AMPbinding can
induce the ordering of the b1-b2 hairpin that functions as
a cap to enclose the active site. This cap is disordered
when there is no bound ligand, as in the unbound subunit
of both mini- and full-length TrpRS. Therefore, ATP still
functions as an allosteric effector in human TrpRS. Instead
of inducing the opening and closing of the active site cleft,
it engages the eukaryote-specific patch, especially the
b hairpin, as a critical component for aminoacylation in
human TrpRS (Figure 7B).
Figure 7. Human and B. stearothermophilus TrpRSs Use
a Distinct Mechanism to Close the Active Site for Catalysis
(A) InB. stearothermophilus TrpRS, ligand binding induces a 13 hinge-
like motion—between the Rossmann fold domain and the anticodon
recognition domain—to close the ATP binding cleft.
(B) Human TrpRS stays in a conformation similar to the closed confor-
mation of B. stearothermophilus TrpRS. Ligand binding engages the
b1-b2 hairpin (from the eukaryote-specific patch) to cap the active site.802 Structure 15, 793–805, July 2007 ª2007 Elsevier Ltd All rigDISCUSSION
We set out to address three specific questions that
centered, respectively, on the reason for the lack of
aminoacylation activity of T2-TrpRS (even though it en-
compassed all and more of the sequence of the ortholo-
gous, active bacterial enzyme), the explanation for the
missing landmark lysine of the KMSKS motif that is used
widely by class I synthetases for ATP recognition, and,
third, how the ‘‘open-closed’’ mechanism for ATP binding
of the bacterial enzyme could be possible when the critical
lysine (K352) was missing. The answers to the first two
questions were found in a crucial (for ATP binding) b1-b2
hairpin of the eukaryote-specific patch that is ablated in
T2-TrpRS, and the remarkable recruitment of an arginine
(R162) that is almost 200 amino acids upstream in the se-
quence from the missing hallmark lysine. That arginine is
not only distal in the sequence from the missing K352
but also spatially repositions the needed interaction with
ATP. Thus, two new features—the b1-b2 hairpin and
R162—shift a critical substrate interaction to the N termi-
nus of the sequence.
For the third question, the importance of the dramatic
shift of a critical substrate interaction to the N-terminal,
eukaryote-specific portion of the sequence was rein-
forced. This shift is accompanied by the creation of a
eukaryote-specific active site ‘‘cap.’’ This cap gives sub-
strate recognition in human TrpRS a novel mechanism
not seen or even possible in the bacterial ortholog. The
hinged open-close conformational change of the bacterial
system was not observed. Instead, a distinct mechanism
is used for human TrpRS to enclose the active site in re-
sponse to ligand binding. This mechanism involves the
b hairpin, which could only be resolved with bound ligand,
which caps the active site to initiate catalysis.
When the surrogate R162 is replaced by alanine, the
roughly 60-fold elevation in Km for ATP amounts to about
2.4 kcal mol1 interaction energy. Essentially all of this
energy is regained when A352 is then replaced with
K352 (Table 3). Thus, even though the charged guanidino
side chain of R162 approaches the ATP phosphate from
the side opposite the approach of the charged 3-lysine
of the landmark lysine (Figure 4), the energetic conse-
quences are about the same. This similarity in energies,
in spite of the different spatial configurations of their es-
sential ATP interaction, may be part of the reason that
the recruitment of a distal arginine is even possible. How-
ever, the double mutant R162A/A352K enzyme did not re-
cover its catalytic constant (Table 3). This failure to recover
catalysis, in spite of a strong substrate binding interaction,
makes difficult a natural reversion of the sequence to re-
generate K352. (A regeneration of K352 would make it
easier to lose the N-terminal extension.) Thus, to retain
the N-terminal extension that ends right before R162, se-
lective pressure to keep the surrogate arginine operates
strongly on the catalytic side, and not as much on the
binding side.
Interestingly, the surrogate Arg162 is just after the N ter-
minus of the core enzyme that is common to TrpRSs in allhts reserved
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the beginning of the core enzyme. As seen above, another
critical element is the essential b1-b2 hairpin, which is at
the beginning of the eukaryote-specific patch that starts
around Glu82 and ends at approximately Lys154. Thus,
from the standpoint of selective pressure, these two com-
ponents—Arg162 and the hairpin—are strategically
placed to bracket and retain the eukaryote-specific patch.
Remarkably, the ‘‘auxiliary’’ TrpRS (TrpRS II) from Dein-
ococcus radiodurans has the appearance of evolutionary
intermediate between prokaryotic and eukaryotic TrpRSs.
Although sharing higher sequence similarity with the bac-
terial TrpRS, D. radiodurans TrpRS II is structurally more
similar to the human than to the B. stearothermophilus en-
zyme (Buddha and Crane, 2005). (Consistently, much less
open-closed conformational change was observed with
the D. radiodurans enzyme.) The KMSKS signature is pre-
served in the sequence, but the second lysine no longer is
engaged in ATP binding. Strikingly, an arginine (R30),
which is adjacent to the equivalent R162 of human TrpRS,
emerged for ATP binding in D. radiodurans TrpRS II.
Among all class I tRNA synthetases, only TrpRS and
TyrRS have lost their second lysine of the KMSKS motif
during evolution. Some eukaryotic TyrRSs including hu-
man have a KMSSS motif. In that instance, potassium
was indicated to functionally replace the second lysine
for binding to ATP phosphates (Austin and First, 2002).
In our previously solved crystal structure of human mini-
TyrRS bound with tyrosinol (PDB ID code 1Q11), although
the KMSSS loop was disordered in the structure, presum-
ably because of the absence of ATP in the crystal, a potas-
sium ion was found in the ATP binding site coordinating
with residues mostly from the 11 amino acid signature
sequence that ends in the tetrapeptide HVAY (the HIGH
sequence) (Webster et al., 1984) (see Figure S1 in the Sup-
plemental Data available with this article online). The loca-
tion of the potassium ion is adjacent to the phosphate
groups of an ATP molecule modeled in the active site,
consistent with the functional observation. Thus, these
two closely related synthetases—TyrRS and TrpRS—
have developed different strategies to replace the missing
K in eukaryotes. In the case of TyrRS, the strategy is rela-
tively simple, when compared to the elaborate scheme
developed by TrpRS. This difference in strategies is con-
sistent with the lack, in TyrRS, of an appended extension
tightly linked to catalysis.
Possibly, in lower eukaryotes, the eukaryote-specific
patch is associated with an unidentified, novel function
of TrpRS. Expanded functions of tRNA synthetases in
lower eukaryotes are known, such as the roles in RNA
splicing of TyrRS in Neurospora crassa and LeuRS in
S. cerevisiae (Hsu et al., 2006; Myers et al., 2002) and in
transcription termination of GlyRS in S. cerevisiae (Johan-
son et al., 2003). In vertebrates, TrpRSs have both the VSE
and eukaryote-specific patch appended to the N termi-
nus. We imagine that evolution added these components
in a progressive way, as the synthetases developed
expanded functions. Thus, in basal eukaryotes, only the
eukaryote-specific patch is present, whereas in higherStructure 15eukaryotes, including humans, the VSE is added on to
the patch. For the cytokine activity of human TrpRS, the
VSE has a clear regulatory role. But whether the eukary-
ote-specific patch of human TrpRS has a direct role in
the expanded function, or whether it compensates for
a perturbation in the aminoacylation activity caused by
a new function emerging from within the core catalytic
unit, is unknown and remains a topic for future investi-
gation.
EXPERIMENTAL PROCEDURES
Crystallization of Human Mini-TrpRS
Human mini-TrpRS(GD) was prepared as described (Wakasugi et al.,
2002), and maintained in a stock solution of 10 mM HEPES (pH 7.5),
20 mM KCl, 0.02% NaN3, 2 mM b-mercaptoethanol. Initial crystalli-
zation trials were conducted using the proprietary high-throughput
protein crystallization platform developed at Syrrx (La Jolla, CA,
USA) as described previously (Yang et al., 2002). Single crystals
were obtained by vapor diffusion of sitting drops (2 ml of protein sample
and 2 ml of reservoir solution) against a reservoir of 2% PEG 8000,
0.1 M MES/Na MES (pH 6.32) at 4C.
Data Collection and Structure Determination
of Human Mini-TrpRS(GD)
X-ray data from a flash-frozen crystal of mini-TrpRS(GD) were col-
lected with beamline 9-2 at the Stanford Synchrotron Radiation Labo-
ratory. Data were integrated and scaled with HKL2000 (Otwinowski
andMinor, 1997). The structure was determined bymolecular replace-
ment using a starting model derived from the crystal structure of the
full-length TrpRS (Yang et al., 2003). Rotational and translational
searches were conducted in CNS (Adams et al., 1998), on data in
the range of 20–4 A˚. The structure was refined by cycles of manual
model adjustment using O (Jones et al., 1991), and subsequent simu-
lated annealing refinementwas performed using CNS. The final Rwork is
25.35% and Rfree is 29.75% at 2.0 A˚. Table 2 summarizes data collec-
tion and refinement statistics.
Modeling of Human TrpRS/ATP Complex
The human TrpRS/ATP complex was modeled by overlapping the
adenosine moiety of ATP from the closed B. stearothermophilus
TrpRS/ATP complex (PDB code: 1M83) with the same moiety of the
bound Trp-AMP in the human TrpRS(GD) structure. Subtle conforma-
tional perturbations of Ser165 and Lys200 were observed when the
structures of mini-TrpRS(GD) and full-length TrpRS(GD) were com-
pared with the structure of mini-TrpRS(GY) (PDB code: 1ULH). The
conformations of Ser165 and Lys200 in the GY structure make more
optimum ATP interactions in the model, consistent with a 10-fold KM
decrease for ATP in aminoacylation (Ewalt et al., 2005). Therefore,
we adjusted the conformations of Ser165 and Lys200 according to
the GY structure in our model of the TrpRS/ATP complex.
Isothermal Titration Calorimetry
ITC was performed using an Omega titration calorimeter (Microcal,
Northampton, MA, USA) as described previously by Wiseman et al.
(1989). Proteins were dialyzed overnight in 20 mM sodium phosphate
buffer (pH 7.5) containing 150 mM NaCl and the final dialysate was
used to prepare ligand solutions. Typically, 700 mM ligand solution
was added to 70 mM protein (present in the sample cell, volume =
1.34 ml) as a 2 ml injection followed by thirty 6 ml injections using a
syringe rotating at 400 rpm. An interval of 3 min between successive
injections was given for the baseline to stabilize. All titrations were car-
ried out at 25C.
One of the requirements for determining binding constants on an
Omega calorimeter is that the C values should lie between 1 and
1000 (Wiseman et al., 1989). The experimental conditions ensured, 793–805, July 2007 ª2007 Elsevier Ltd All rights reserved 803
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as the association constant and [M] as the macromolecule concentra-
tion. Heats of dilution of ligand were subtracted from the titration data.
The data so obtained were fitted via the nonlinear least-squares mini-
mization method to determine binding constants using Origin software
(Microcal).
Construction, Expression, and Purification of TrpRS
Active Site Mutations
Constructs of 6-His-tagged full-length TrpRSandT2-TrpRSwere avail-
able from previous studies (Wakasugi et al., 2002). The single mutant
R162A and the double mutant R162A/A352K were constructed into
full-length human TrpRS(SY), themost common apparent polymorphic
sequence variant (Ewalt et al., 2005), by standard site-directed muta-
genesis using the QuikChange mutagenesis kit (Stratagene, La Jolla,
CA, USA). All TrpRS proteins were expressed in the Escherichia coli
BL21(DE3) strain at 37C under IPTG induction, and were purified by
Ni-NTA affinity chromatography. After purification, proteins were
stored in 20 mM Tris-HCl (pH 8.0), 200 mM NaCl, 20% glycerol in
a 80C freezer.
Stopped-Flow Fluorescence Studies
The formation of tryptophanyl adenylate, catalyzed by wild-type and
mutant TrpRS proteins, was monitored by the change in tryptophan
fluorescence at 340 nm. One syringe of the stopped-flow apparatus
(KinTek, Austin, TX, USA) contained 1 mM L-tryptophan and 0.1 mM
wild-type TrpRS or 200 mM L-tryptophan and 30 mM TrpRS mutants,
plus 4 U/ml dialyzed IPPase (Roche, Indianapolis, IN, USA) in
100 mM Tris-HCl (pH 8.0), 1 mM b-mercaptoethanol, 0.1 mM EDTA,
1 mM MgCl2. The other syringe contained various concentrations of
Mg-ATP (0.1–380 mM), 1 mM or 200 mM L-tryptophan (for wild-type
or mutants), and 4 U/ml dialyzed IPPase in the same buffer. The
decrease in fluorescence (excitation at 290 nm, emission at 340 nM,
excitation band pass 2 nm, emission band pass 5 nm) due to amino-
acyl adenylate formation on mixing was monitored on a Fluoromax-3
spectrofluorometer (HORIBA, Edison, NJ, USA) at 23C.
Supplemental Data
Supplemental Data include one figure and can be found with this arti-
cle online at http://www.structure.org/cgi/content/full/15/7/793/DC1/.
ACKNOWLEDGMENTS
This work was supported by grants CA92577 from the National Cancer
Institute and GM15539 from the National Institutes of Health, and by
a grant from the National Foundation for Cancer Research.
Received: March 26, 2007
Revised: May 7, 2007
Accepted: May 8, 2007
Published: July 17, 2007
REFERENCES
Aboagye-Mathiesen, G., Ebbesen, P., von der Maase, H., and Celis,
J.E. (1999). Interferon g regulates a unique set of proteins in fresh
human bladder transitional cell carcinomas. Electrophoresis 20, 344–
348.
Adams, P.D., Rice, L.M., and Brunger, A.T. (1998). Crystallography &
NMR System: a new software suite for macromolecular structure de-
termination. Curr. Opin. Struct. Biol. 8, 606–611.
Arnez, J.G., and Moras, D. (1997). Structural and functional consider-
ations of the aminoacylation reaction. Trends Biochem. Sci. 22, 211–
216.
Austin, J., and First, E.A. (2002). Potassium functionally replaces the
second lysine of the KMSKS signature sequence in human tyrosyl-
tRNA synthetase. J. Biol. Chem. 277, 20243–20248.804 Structure 15, 793–805, July 2007 ª2007 Elsevier Ltd AllBateman, A., Birney, E., Cerruti, L., Durbin, R., Etwiller, L., Eddy, S.R.,
Griffiths-Jones, S., Howe, K.L., Marshall, M., and Sonnhammer, E.L.
(2002). The Pfam protein families database. Nucleic Acids Res. 30,
276–280.
Buddha, M.R., and Crane, B.R. (2005). Structures of tryptophanyl-
tRNA synthetase II from Deinococcus radiodurans bound to ATP and
tryptophan. Insight into subunit cooperativity and domain motions
linked to catalysis. J. Biol. Chem. 280, 31965–31973.
Cantor, C., and Schimmel, P. (1980). Biophysical Chemistry. Part III:
The Behavior of Biological Macromolecules (San Francisco: W.H.
Freeman).
Doublie, S., Bricogne, G., Gilmore, C., and Carter, C.W., Jr. (1995).
Tryptophanyl-tRNA synthetase crystal structure reveals an unex-
pected homology to tyrosyl-tRNA synthetase. Structure 3, 17–31.
Ewalt, K.L., Yang, X.L., Otero, F.J., Liu, J., Slike, B., and Schimmel, P.
(2005). Variant of human enzyme sequesters reactive intermediate.
Biochemistry 44, 4216–4221.
Fett, R., and Knippers, R. (1991). The primary structure of human glu-
taminyl-tRNA synthetase. A highly conserved core, amino acid repeat
regions, and homologies with translation elongation factors. J. Biol.
Chem. 266, 1448–1455.
Ge, Q., Trieu, E.P., and Targoff, I.N. (1994). Primary structure and func-
tional expression of human glycyl-tRNA synthetase, an autoantigen in
myositis. J. Biol. Chem. 269, 28790–28797.
Han, J.M., Park, S.G., Lee, Y., and Kim, S. (2006). Structural separation
of different extracellular activities in aminoacyl-tRNA synthetase-
interacting multi-functional protein, p43/AIMP1. Biochem. Biophys.
Res. Commun. 342, 113–118.
Hirakata, M., Suwa, A., Takeda, Y., Matsuoka, Y., Irimajiri, S., Targoff,
I.N., Hardin, J.A., and Craft, J. (1996). Autoantibodies to glycyl-transfer
RNA synthetase in myositis. Association with dermatomyositis and im-
munologic heterogeneity. Arthritis Rheum. 39, 146–151.
Howard, O.M., Dong, H.F., Yang, D., Raben, N., Nagaraju, K., Rosen,
A., Casciola-Rosen, L., Hartlein, M., Kron, M., Yiadom, K., et al. (2002).
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoanti-
gens in myositis, activate chemokine receptors on T lymphocytes and
immature dendritic cells. J. Exp. Med. 196, 781–791.
Hsu, J.L., Rho, S.B., Vannella, K.M., and Martinis, S.A. (2006). Func-
tional divergence of a unique C-terminal domain of leucyl-tRNA syn-
thetase to accommodate its splicing and aminoacylation roles. J.
Biol. Chem. 281, 23075–23082.
Ilyin, V.A., Temple, B., Hu, M., Li, G., Yin, Y., Vachette, P., and Carter,
C.W., Jr. (2000). 2.9 A˚ crystal structure of ligand-free tryptophanyl-
tRNA synthetase: domain movements fragment the adenine nucleo-
tide binding site. Protein Sci. 9, 218–231.
Jeong, E.J., Hwang, G.S., Kim, K.H., Kim, M.J., Kim, S., and Kim, K.S.
(2000). Structural analysis of multifunctional peptide motifs in human
bifunctional tRNA synthetase: identification of RNA-binding residues
and functional implications for tandem repeats. Biochemistry 39,
15775–15782.
Johanson, K., Hoang, T., Sheth, M., and Hyman, L.E. (2003). GRS1,
a yeast tRNA synthetase with a role in mRNA 3’ end formation.
J. Biol. Chem. 278, 35923–35930.
Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. (1991). Im-
proved methods for building protein models in electron density maps
and the location of errors in these models. Acta Crystallogr. A 47,
110–119.
Kapustina, M., and Carter, C.W., Jr. (2006). Computational studies
of tryptophanyl-tRNA synthetase: activation of ATP by induced-fit.
J. Mol. Biol. 362, 1159–1180.
Kim, M.J., Park, B.J., Kang, Y.S., Kim, H.J., Park, J.H., Kang, J.W.,
Lee, S.W., Han, J.M., Lee, H.W., and Kim, S. (2003). Downregulation
of FUSE-binding protein and c-myc by tRNA synthetase cofactor
p38 is required for lung cell differentiation. Nat. Genet. 34, 330–336.rights reserved
Structure
TrpRS Active Site Adapted for Cytokine FunctionKise, Y., Lee, S.W., Park, S.G., Fukai, S., Sengoku, T., Ishii, R.,
Yokoyama, S., Kim, S., and Nureki, O. (2004). A short peptide insertion
crucial for angiostatic activity of human tryptophanyl-tRNA synthe-
tase. Nat. Struct. Mol. Biol. 11, 149–156.
Kobayashi, T., Nureki, O., Ishitani, R., Yaremchuk, A., Tukalo, M.,
Cusack, S., Sakamoto, K., and Yokoyama, S. (2003). Structural basis
for orthogonal tRNA specificities of tyrosyl-tRNA synthetases for ge-
netic code expansion. Nat. Struct. Biol. 10, 425–432.
Myers, C.A., Kuhla, B., Cusack, S., and Lambowitz, A.M. (2002). tRNA-
like recognition of group I introns by a tyrosyl-tRNA synthetase. Proc.
Natl. Acad. Sci. USA 99, 2630–2635.
Otani, A., Slike, B.M., Dorrell, M.I., Hood, J., Kinder, K., Ewalt, K.L.,
Cheresh, D., Schimmel, P., and Friedlander, M. (2002). A fragment of
human TrpRS as a potent antagonist of ocular angiogenesis. Proc.
Natl. Acad. Sci. USA 99, 178–183.
Otwinowski, Z. andMinor,W., eds. (1997). Processing of X-RayDiffrac-
tion Data Collected in Oscillation Mode (San Diego: Academic Press).
Park, B.J., Kang, J.W., Lee, S.W., Choi, S.J., Shin, Y.K., Ahn, Y.H.,
Choi, Y.H., Choi, D., Lee, K.S., and Kim, S. (2005a). The haploinsuffi-
cient tumor suppressor p18 upregulates p53 via interactions with
ATM/ATR. Cell 120, 209–221.
Park, S.G., Ewalt, K.L., and Kim, S. (2005b). Functional expansion of
aminoacyl-tRNA synthetases and their interacting factors: new per-
spectives on housekeepers. Trends Biochem. Sci. 30, 569–574.
Park, S.G., Kim, H.J., Min, Y.H., Choi, E.C., Shin, Y.K., Park, B.J., Lee,
S.W., and Kim, S. (2005c). Human lysyl-tRNA synthetase is secreted to
trigger proinflammatory response. Proc. Natl. Acad. Sci. USA 102,
6356–6361.
Retailleau, P., Yin, Y., Hu, M., Roach, J., Bricogne, G., Vonrhein, C.,
Roversi, P., Blanc, E., Sweet, R.M., and Carter, C.W., Jr. (2001).
High-resolution experimental phases for tryptophanyl-tRNA synthe-
tase (TrpRS) complexed with tryptophanyl-5’AMP. Acta Crystallogr.
D Biol. Crystallogr. 57, 1595–1608.
Retailleau, P., Huang, X., Yin, Y., Hu, M., Weinreb, V., Vachette, P.,
Vonrhein, C., Bricogne, G., Roversi, P., Ilyin, V., and Carter, C.W., Jr.
(2003). Interconversion of ATP binding and conformational free ener-
gies by tryptophanyl-tRNA synthetase: structures of ATP bound to
open and closed, pre-transition-state conformations. J. Mol. Biol.
325, 39–63.
Retailleau, P., Weinreb, V., Hu, M., and Carter, C.W., Jr. (2007). Crystal
structure of tryptophanyl-tRNA synthetase complexed with adeno-
sine-5’ tetraphosphate: evidence for distributed use of catalytic
binding energy in amino acid activation by class I aminoacyl-tRNA
synthetases. J. Mol. Biol. 369, 108–128.
Rho, S.B., Lee, J.S., Jeong, E.J., Kim, K.S., Kim, Y.G., and Kim, S.
(1998). A multifunctional repeated motif is present in human bifunc-
tional tRNA synthetase. J. Biol. Chem. 273, 11267–11273.Structure 15,Sampath, P., Mazumder, B., Seshadri, V., Gerber, C.A., Chavatte, L.,
Kinter, M., Ting, S.M., Dignam, J.D., Kim, S., Driscoll, D.M., and Fox,
P.L. (2004). Noncanonical function of glutamyl-prolyl-tRNA synthe-
tase: gene-specific silencing of translation. Cell 119, 195–208.
Shen, N., Guo, L., Yang, B., Jin, Y., and Ding, J. (2006). Structure of
human tryptophanyl-tRNA synthetase in complex with tRNATrp reveals
the molecular basis of tRNA recognition and specificity. Nucleic Acids
Res. 34, 3246–3258.
Tsui, F.W., and Siminovitch, L. (1987). Isolation, structure and expres-
sion of mammalian genes for histidyl-tRNA synthetase. Nucleic Acids
Res. 15, 3349–3367.
Tzima, E., Reader, J.S., Irani-Tehrani, M., Ewalt, K.L., Schwartz, M.A.,
and Schimmel, P. (2003). Biologically active fragment of a human tRNA
synthetase inhibits fluid shear stress-activated responses of endothe-
lial cells. Proc. Natl. Acad. Sci. USA 100, 14903–14907.
Wakasugi, K., and Schimmel, P. (1999). Two distinct cytokines re-
leased from a human aminoacyl-tRNA synthetase. Science 284,
147–151.
Wakasugi, K., Slike, B.M., Hood, J., Otani, A., Ewalt, K.L., Friedlander,
M., Cheresh, D.A., and Schimmel, P. (2002). A human aminoacyl-tRNA
synthetase as a regulator of angiogenesis. Proc. Natl. Acad. Sci. USA
99, 173–177.
Webster, T., Tsai, H., Kula, M., Mackie, G.A., and Schimmel, P. (1984).
Specific sequence homology and three-dimensional structure of an
aminoacyl transfer RNA synthetase. Science 226, 1315–1317.
Wiseman, T., Williston, S., Brandts, J.F., and Lin, L.N. (1989). Rapid
measurement of binding constants and heats of binding using a new
titration calorimeter. Anal. Biochem. 179, 131–137.
Yang, X.L., Skene, R.J., McRee, D.E., and Schimmel, P. (2002). Crystal
structure of a human aminoacyl-tRNA synthetase cytokine. Proc. Natl.
Acad. Sci. USA 99, 15369–15374.
Yang, X.-L., Otero, F.J., Skene, R.J., McRee, D.E., Schimmel, P., and
Ribas de Pouplana, L. (2003). Crystal structures that suggest late de-
velopment of genetic code components for differentiating aromatic
side chains. Proc. Natl. Acad. Sci. USA 100, 15376–15380.
Yang, X.L., Otero, F.J., Ewalt, K.L., Liu, J., Swairjo, M.A., Kohrer, C.,
RajBhandary, U.L., Skene, R.J., McRee, D.E., and Schimmel, P.
(2006). Two conformations of a crystalline human tRNA synthetase-
tRNA complex: implications for protein synthesis. EMBO J. 25,
2919–2929.
Yu, Y., Liu, Y., Shen, N., Xu, X., Xu, F., Jia, J., Jin, Y., Arnold, E., and
Ding, J. (2004). Crystal structure of human tryptophanyl-tRNA synthe-
tase catalytic fragment: insights into substrate recognition, tRNA bind-
ing, and angiogenesis activity. J. Biol. Chem. 279, 8378–8388.
Accession Numbers
Coordinates for human mini-TrpRS(GD) have been deposited in the
Protein Data Bank under code 1R6U.793–805, July 2007 ª2007 Elsevier Ltd All rights reserved 805
